90% effective Pfizer pill against Covid-19


The final analysis of the antiviral pill against Covid-19 disease protects 90% against severe disease and coronavirus death, according to data presented by the pharmaceutical industry. Meanwhile, preliminary research has shown that its vaccine is 70% against the new “O” variant.

As early as last month, the pharmaceutical industry had announced that the pill was about 89% effective in preventing hospitalization and preventing death compared to placebo, based on mid-term trials in about 1,200 people. The data released today includes an additional 1,000 people. None of those receiving Pfizer treatment reportedly died, while 12 of those who received placebo died.

Pfizer Covid-19 medicine, if approved by the competent authorities, will be marketed under the brand name Paxlovid.

It should be noted that for the drug to be effective, it should be administered every 12 hours for a period of five days, and treatment should be started shortly after the onset of Covid-19 symptoms.

Earlier, it was also announced that the Pfizer vaccine protects against hospitalization in the case of the Omicron variant. According to a preliminary study in South Africa, two doses of the Pfizer / BioNTech vaccine against Covid-19 appear to have provided 70% protection against hospitalization in recent weeks in South Africa, at a time when the country is experiencing an outbreak of new variant.

The study, published by South Africa’s largest private health insurance provider, Discovery Health, is based on more than 211,000 positive Covid-19 tests performed from November 15 to December 7. About 78,000 of these were attributed to Omicron, without being fully confirmed, which means that the study could not draw any conclusions about the variant.

The real-world study estimated that, compared with the unvaccinated, two doses of the Pfizer / BioNTech vaccine provided 70% protection against hospitalization during the recent outbreak and 33% protection against infection. According to the same source, this result marks a drop in protection by 80% from infection and by 90% from hospitalization for the Delta variant.

Gleda Gray, chair of the South African Medical Research Council (SAMRC), said it was important that the Pfizer / BioNTech vaccine appeared to offer good protection against serious illness and hospitalization at a time when a highly contagious new variant was being released. . The analysis also shows that protection from care is maintained at all ages, in people aged 18 to 79, with slightly lower levels of protection for the elderly.


Leave A Reply

Your email address will not be published.